Estimaciones de analistas de Wall Street para CAMP4 Therapeutics Corporation (CAMP): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-08-13 | $-0.58 | $-0.21 | -174.3% |
| 2026-05-07 | $-0.32 | $-0.21 | -52.4% |
| 2026-03-05 | $-0.87 | $-0.31 | -180.6% |
| 2025-11-06 | $-0.55 | $-0.47 | -17.0% |
| 2025-08-14 | $-0.62 | $-0.67 | +7.5% |
| 2025-05-13 | $-0.62 | $-0.70 | +11.4% |
| 2025-03-27 | $-0.77 | $-0.91 | +15.4% |
| 2025-02-20 | $-24.19 | $-0.82 | -2850.0% |
Ratios de valoración
| Precio / Valor contable | -362.08 |
| EV / EBITDA | -0.12 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $351.1M | $365.9M | $363.8M | $366.1M | $308.6M | $295.8M | $294.9M | $350000 | $652000 | $3.5M |
| Coste de Ventas | $207.8M | $215.0M | $216.0M | $222.8M | $186.2M | $174.0M | $185.9M | 0 | 0 | $1.6M |
| Beneficio Bruto | $143.4M | $150.9M | $147.8M | $143.3M | $122.4M | $121.9M | $109.0M | $350000 | $652000 | $1.9M |
| I+D | $22.0M | $25.8M | $27.7M | $29.4M | $25.8M | $28.4M | $24.6M | $40.6M | $38.8M | $38.2M |
| Generales y Administrativos | $104.9M | $102.2M | $81.0M | $118.2M | $95.3M | $100.9M | $99.2M | $11.6M | $14.9M | $17.4M |
| Gastos Operativos | $142.0M | $142.9M | $120.1M | $160.0M | $125.9M | $134.8M | $133.7M | $52.2M | $53.7M | $53.9M |
| Beneficio Operativo | $1.3M | $8.0M | $19.7M | -$16.8M | -$6.8M | -$13.5M | -$24.7M | -$51.9M | -$53.1M | -$52.1M |
| EBITDA | $24.7M | $31.4M | $47.1M | $15.2M | $8.5M | -$2.6M | -$25.1M | -$50.2M | -$51.4M | -$50.4M |
| Gastos por Intereses | $9.9M | $10.3M | $16.7M | $20.1M | $5.8M | $5.2M | $6.3M | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$7.0M | $28.7M | $23.9M | -$58.3M | -$20.6M | -$30.1M | -$31.3M | -$49.3M | -$51.8M | -$80.4M |
| Impuestos | -$1.1M | $10.7M | -$1.3M | $20.5M | $561000 | $1.1M | $1.2M | 0 | 0 | 0 |
| Beneficio Neto | -$7.2M | $16.6M | $18.4M | -$78.8M | -$56.3M | -$28.0M | -$32.5M | -$49.3M | -$51.8M | -$80.4M |
| BPA | $-0.20 | $0.47 | $0.53 | $-2.35 | $0.00 | $0.00 | $-0.90 | $-4.07 | $-2.66 | $-2.65 |
| BPA Diluido | $-0.20 | $0.46 | $0.52 | $-2.34 | $0.00 | $0.00 | $-0.90 | $-4.07 | $-2.66 | $-2.65 |
| Acciones en Circulación (Diluidas) | $35.9M | $36.1M | $35.3M | $33.7M | $1.5M | $1.5M | $36.1M | $12.1M | $19.5M | $30.4M |
Precio
| Precio | $3.86 |
| Capitalización | $82M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ACRV · ALXO · ATYR · BMEA · HYFT · PMVP · QNCX
Explorar sector: Healthcare · Biotechnology
Más secciones de CAMP: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones